Premium
Assessment of βrenergic Blockade with Propranolol in Patients with Cirrhosis
Author(s) -
Bercoff Eric,
Bataille Christian,
Pariente Alexandre E.,
Valla Dominique,
Delhotal Brigitte,
Lebrec Didier
Publication year - 1984
Publication title -
hepatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.488
H-Index - 361
eISSN - 1527-3350
pISSN - 0270-9139
DOI - 10.1002/hep.1840040317
Subject(s) - propranolol , medicine , cirrhosis , heart rate , chronotropic , blockade , oral administration , portal venous pressure , blood pressure , endocrinology , anesthesia , portal hypertension , receptor
Fourteen patients with cirrhosis and bleeding esophageal varices were treated with propranolol. The dose of propranolol was determined by decreasing the resting heart rate by 25% 12 hr after an oral dose of propranolol which was given twice a day. Significant decreases in the hepatic venous pressure gradient and cardiac output after 1 month of propranolol administration was observed. To assess β‐adrenergic blockade, the isoproterenol test and plasma propranolol levels were evaluated. Increasing doses of isoproterenol were injected to increase the resting heart rate 25 beats per minute (chronotropic dose 25 or CD25). Plasma propranolol concentrations were measured in blood samples drawn 4 hr after the last oral dose. The mean CD25 was 5 ± 2 μg before and 146 ± 84 μg after 1 month of propranolol administration. The plasma propranolol level after 1 month of drug administration was 0.69 ± 0.47 μM per liter i.e. 2.33 ± 1.59 /ig per ml. A significant correlation was found between the CD25 measured after continuous propranolol administration and plasma propranolol level. In conclusion, the efficacy of β‐adrenergic blockade was estimated by the isoproterenol test which correlates with the plasma propranolol level in patients with cirrhosis. This study suggests that the isoproterenol test is useful in assessing β‐adrenergic blockade with propranolol in patients with cirrhosis.